From:	SANTE PROCUREMENT			
Sent:	lundi 31 août 2020 16:15			
To:				
Subject:	ANSWER: CALL FOR TENDERS SANTE/2020/C3/054 – Questions 2			
Dear				
Please find helow the answer to the questions from 28 August. The question highlighted is still pending. We will try to come back to you as soon as possible. The answer to questions from a second email will be answered by a separate email.				
Best regards				
List of documents to be submitted wit	h the tender or during the procedure (Annex 1)			
•				
Subsectional and American Section 1	artina 2.4.2)			
Subcontracting (Annex 4, Annex 5, Se	Ruan 2.4.2)			
•				
4				
•				
Evidence that the nerson(s) signing	g the documents under 1.5, 1.7, 2.1 and 4.1 is (are) authorised			
representative(s) of the entity (Annex				
•				
•				

•	
Declar	ation on Honour on exclusion and selection criteria (Annex 2)
•	
	Financial Offer (Annex 6)
•	
•	
•	
•	

•	
•	
Advanc	red Purchase Agreement (Annex 8)
•	
•	
•	
•	

•

•

Evidence of technical and professional capacity T1 to T3 (Section 3.2.3)
Power of Attorney (Annex 1, Section 1.7)
Evidence of Non-Exclusion (Annex 2, Section 3.1 and Section VI)
Declaration on Honour on exclusion and selection criteria (Annex 2)



## Confidentiality

•

## **SANTE PROCUREMENT TEAM**



From

Sent: Friday, August 28, 2020 10:16 AM

**To:** SANTE PROCUREMENT

**Subject:** CALL FOR TENDERS SANTE/2020/C3/054 – Questions

To Whom It May Concern:

Moderna Switzerland GmbH ("Moderna") welcomes the opportunity to submit a proposal for the tender SANTE/2020/C3/054 for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States. In anticipation of submitting a proposal, please see attached questions submitted by Moderna seeking clarification on various elements of tender SANTE/2020/C3/054.

Please let me know if you have any problems opening the document. Moderna looks forward to receiving your responses and submitting a proposal for the tender.

Regards.		
	Moderna Therapeuti	icc
	iviouerna rnerapeuti	CS

## Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.